<code id='3E79D20EEC'></code><style id='3E79D20EEC'></style>
    • <acronym id='3E79D20EEC'></acronym>
      <center id='3E79D20EEC'><center id='3E79D20EEC'><tfoot id='3E79D20EEC'></tfoot></center><abbr id='3E79D20EEC'><dir id='3E79D20EEC'><tfoot id='3E79D20EEC'></tfoot><noframes id='3E79D20EEC'>

    • <optgroup id='3E79D20EEC'><strike id='3E79D20EEC'><sup id='3E79D20EEC'></sup></strike><code id='3E79D20EEC'></code></optgroup>
        1. <b id='3E79D20EEC'><label id='3E79D20EEC'><select id='3E79D20EEC'><dt id='3E79D20EEC'><span id='3E79D20EEC'></span></dt></select></label></b><u id='3E79D20EEC'></u>
          <i id='3E79D20EEC'><strike id='3E79D20EEC'><tt id='3E79D20EEC'><pre id='3E79D20EEC'></pre></tt></strike></i>

          fashion

          fashion

          author:leisure time    Page View:8
          David Sabatini
          Wikimedia Commons

          Former MIT and Whitehead Institute star biologist David Sabatini, who lost his positions after he was accused of violating sexual harassment policies in 2021, is resuming his science career, taking a post at a Czech research institute in Prague.

          Sabatini, of Cambridge, confirmed in a phone call from Prague that he has accepted a position as a “senior group leader” at the Institute of Organic Chemistry and Biochemistry, known as IOCB Prague. Sabatini said he will be recruiting staff and running a laboratory in the Czech Republic capital to investigate scientific questions in the areas of cell growth and metabolism, similar to his past research in Cambridge.

          advertisement

          “I’m very grateful to be given the opportunity to do science again,” said Sabatini, who began working at the institute last month.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more
          Genentech weighs delaying cancer therapy after drug pricing law
          Genentech weighs delaying cancer therapy after drug pricing law

          GenentechCEOAlexanderHardyGenentechWASHINGTON—PlentyofpharmaceuticalexecutiveshavedecriedDemocrats’n

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          340B reform proposal comes out of Senate working group

          Sen.JohnThuneisoneofagroupoflawmakersthatisworkingon340Breformlegislation.BRENDANSMIALOWSKI/AFPviaGe